Syneron Bio

Stub active Updated Apr 3, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Beijing, China
Latest Stage Series B
Total Raised $250M
Website https://www.syneronbio.com
Sector
biotech drug-discovery healthcare

About

Syneron Bio is a Beijing-based biotech company specializing in intelligent platform-driven macrocyclic peptide drug discovery 1. The company operates the proprietary Synova platform and develops treatments across oncology, autoimmune, metabolic, and rare diseases 1. The company previously closed nearly $100M in Series A and A+ rounds with backing from AstraZeneca and its China joint fund 2.

Funding History

Date Round Amount Lead Co-investors
2025 Series A/A+ ~$100M AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, Lenovo Capital 2
2026-04-03 Series B $150M Decheng Capital, CDH VGC ADIA subsidiary, True Light Capital (Temasek), Qiming Venture Partners, BioTrack Capital 1

Total raised to date: ~$250M 12.

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. PR Newswire, “Syneron Bio Announces Completion of $150 Million Series B Financing,” April 3, 2026. https://www.prnewswire.com/news-releases/syneron-bio-announces-completion-of-150-million-series-b-financing-302733591.html↩↩↩↩

  2. DealStreetAsia, “AstraZeneca, its China joint fund lead nearly $100m financing in Syneron Bio,” 2025. https://www.dealstreetasia.com/stories/astrazeneca-syneron-bio-466314↩↩↩